Literature DB >> 29978065

Roles of African Swine Fever Virus Structural Proteins in Viral Infection.

Ning Jia1, Yunwen Ou1,2, Zygmunt Pejsak3, Yongguang Zhang2, Jie Zhang2.   

Abstract

African swine fever virus (ASFV) is a large, double-stranded DNA virus and the sole member of the Asfarviridae family. ASFV infects domestic pigs, wild boars, warthogs, and bush pigs, as well as soft ticks (Ornithodoros erraticus), which likely act as a vector. The major target is swine monocyte-macrophage cells. The virus can cause high fever, haemorrhagic lesions, cyanosis, anorexia, and even fatalities in domestic pigs. Currently, there is no vaccine and effective disease control strategies against its spread are culling infected pigs and maintaining high biosecurity standards. African swine fever (ASF) spread to Europe from Africa in the middle of the 20th century, and later also to South America and the Caribbean. Since then, ASF has spread more widely and thus is still a great challenge for swine breeding. The genome of ASFV ranges in length from about 170 to 193 kbp depending on the isolate and contains between 150 and 167 open reading frames (ORFs). The ASFV genome encodes 150 to 200 proteins, around 50 of them structural. The roles of virus structural proteins in viral infection have been described. These proteins, such as pp220, pp62, p72, p54, p30, and CD2v, serve as the major component of virus particles and have roles in attachment, entry, and replication. All studies on ASFV proteins lay a good foundation upon which to clarify the infection mechanism and develop vaccines and diagnosis methods. In this paper, the roles of ASFV structural proteins in viral infection are reviewed.

Entities:  

Keywords:  African swine fever virus; review; structural proteins; viral infection

Year:  2017        PMID: 29978065      PMCID: PMC5894393          DOI: 10.1515/jvetres-2017-0017

Source DB:  PubMed          Journal:  J Vet Res        ISSN: 2450-7393            Impact factor:   1.744


Introduction

African swine fever (ASF), first identified in Kenya in 1921, had only been reported in the sub-Saharan region before 1957; however, the virus had spread to other regions and this led to an ASF outbreak in Lisbon, Portugal, in that year (59). Due to successful biosecurity regulations, African swine fever virus (ASFV) was then eradicated from most affected regions. However, it still remains endemic in sub-Saharan countries and Sardinia (18). So far, ASF has been identified in the Caucasus and Central and Eastern European regions, and in countries such as Armenia, Azerbaijan, Belarus, Ukraine, Estonia, Latvia, Lithuania, and Poland (1, 18, 56, 68). In Poland, ASFV was detected for the first time in Sokółka county in 2014. Since February 2014 and at the time of writing, 80 ASF cases in wild boars and 3 outbreaks in domestic pigs have been diagnosed in Poland (30, 36, 71). The disease has caused heavy economic losses to the pig industry and exerted significant social influence on the world. ASF is caused by ASFV which is a linear, large, double-stranded DNA virus and the only member of the Asfarviridae family (15). Wild pigs such as warthogs and bush pigs, and soft ticks of the Ornithodoros species are the natural hosts of ASFV and they can be persistently infected with no disease signs (18). ASFV can spread between wild pigs and soft ticks by feeding and, infrequently, can spread between wild pigs by direct transmission. Once introduced into the domestic pig population, ASFV can be transmitted directly between pigs and leads to mortality rates approaching 100% (42). The typical clinical signs include high fever, haemorrhagic lesions, cyanosis, anorexia, and ataxia (10). Different organs show severe vascular changes in the acute and sub-acute forms of ASF, such as renal petechiae and diffuse haemorrhage in lymph nodes, pulmonary oedema, disseminate intravascular coagulation, and thrombocytopenia (28). More recent studies found that porcine macrophage and aortic endothelial cells are good natural host cell lines to support a productive ASFV infection in cell culture (26, 53, 74). ASFV is an enveloped DNA virus, and its genome ranges in length from about 170 to 193 kbp (15). The encoded genes are closely spaced in the genome; however, the encoded orientation of neighbouring genes is the same in some genomic regions (20). ASFV has similarities with Poxvirus and Iridovirus, because all of them are cytoplasmic DNA viruses (51). The Spanish BA71V isolate was completely sequenced first, which was well adapted to grow in tissue culture cells. So far, 11 complete ASFV genome sequences have been determined and the numbers of open reading frames (ORFs) are different depending on the isolate (75). The ASFV genome encodes 151 to 167 ORFs. Among them, 110 ORFs are highly conserved in 11 isolates (75). ASFV is icosahedrally symmetric and is a virus which replicates in the cytoplasm of infected cells. ASFV particles are 170 to 190 nm in diameter and are constituted by complex multi-layered structures (66). The encoded structural proteins are involved in genome replication and viral infection (20). Some research results showed that more than 50 proteins are packaged into virions and work in viral infection, such as pp220, pp62, p72, p54, p30, CD2v, p10, p12, p14.5, and p17. pp220 and pp62 are ASFV polyprotein precursors, and the proteins can be proteolytically cleaved into the mature virion proteins. ASFV p54 and p30 are very important antigenic structural proteins. p72 is the major composition of viral icosahedrons, and is very important in forming the viral capsid in the later expression of viral infection. CD2v is a glycoprotein. It may have a role in the pathogenesis of ASFV infection, and a further one in tissue tropism and immune evasion in the host. p10, p12, p14.5, and p17 proteins are involved in ASFV adsorption and virion transfer. Thus these proteins can be exploited to serve as research targets to analyse the infection mechanism of ASFV. In this review, we discuss the encoded structural proteins of ASFV involved in viral infection, and the molecular mechanism of interaction between these proteins and host cells.

pp220 and pp62 proteins

To date, ASFV has been found to have 110 ORFs highly conserved in its viral genome (75). There are two ORFs encoding the ASFV polyprotein precursors pp220 and pp62 (or pp60). pp220 with a relative molecular weight of 281.5 kDa belongs to the late proteins in viral infection. This protein is encoded by gene CP2475L and is cleaved to yield the mature virion proteins p150, p37, p14, and p34 by the virus-encoded SUMO-like protease S273R. pp62 with a relative molecular weight of 60.5 kDa is encoded by gene CP530R, and can be proteolytically cleaved into the mature virion proteins p35 and p15 by S273R (3). p150, p37, p14, p34, p35, and p15 play a crucial role in the assembly process of the viral capsid. They account for approximately 30% of the total amount of viral protein mass, forming the major components of the core shell of the virions (3). Pulse chasing analysis showed that the process of the two polyproteins pp220 and pp62 and virus assembly occur simultaneously. Early research suggested that virus particles assemble in discrete cytoplasmic areas close to the nucleus, referred to as viral factories. Electron microscopic researches showed that virions assemble membranous structures present in the viral factories (4). Further research suggested that processing of polyproteins pp220 and pp62 requires the expression of the major capsid protein p72, and the expression of pp220 lays the foundation for pp62 processing. Proper processing of pp220 and pp62 is an important sign of mature virions (73). Virus particles without a core or lacking infectiveness can appear if the processing of pp220 and pp62 is prevented (4). Gallardo et al. (29) analysed the antigenicity of pp62, p32, and p54 expressed in insect cells, and these recombinant proteins were used as antigens in ELISA and an immunoblot (IB) test for ASF serological diagnosis. The results showed that the reaction specificity in the IB test is higher than in ELISA, and the specificities of pp62 and p32 are higher than that of p54. p37 is one of the major core shell proteins and is cleaved from pp220 by the viral protease S273R that shares sequence similarity with proteases of the SUMO-1 family. p37 is localised to the viral core shell domain and also is the first nucleo-cytoplasmic shuttling protein encoded by ASFV (22). Some research demonstrated that the nuclear export of p37 protein is mediated by both the chromosome region maintenance 1 (CRM1)-dependent and CRM1-independent nuclear export pathways (21). In research on detection of the localisation of p37 protein in ASFV-infected cells it was shown that at early stages of infection, p37 localises in distinct nuclear regions, and at later stages, the protein localises exclusively in the cytoplasm (23). All these results reinforce the importance to the ASFV replication cycle of p37 protein nuclear transport. p34 protein, like p37 protein, is one of the major structural proteins. It was only detected in the membrane fraction, and was only protected from trypsin. Incorrectly processed forms of p34 can be recovered from both the cytosol and membrane fractions (3, 4). A sucrose density centrifugation experiment showed that membrane-associated forms of p34 and p150 are assembled into large structures suggestive of a viral matrix. The majority of the improperly processed forms of p150 can be recovered from the cytosol; however, the correct product of p150 is selectively recruited to membranes (38). p35 and p15 are the mature products of polyprotein pp62, and the relative molecular weights of the two proteins are 35 kDa and 15 kDa respectively. Densitometric analysis of one- and two-dimensional gels demonstrated that the proteins and the pp220-derived products are present in equimolecular amounts in the virus particle. Immunoelectron microscopy showed that the pp62-derived products reside in the core shell which is a matrix-like domain placed between the DNA-containing nucleoid and the inner envelope (72). In summary, pp220, pp62, and their mature proteins have important functions in the assembly of virions and viral infection.

p54 and p30 proteins

p54 and p30 proteins are the structural proteins involved in viral entry, but while the proteins have similar roles during viral infection, their roles are also materially different. p54 encoded by the gene E183L is a very important ASFV antigenic structural protein with a relative molecular weight of 25 kDa. The protein contains a transmembrane domain and a Gly-Gly-X motif, as well as a recognition sequence for processing several ASFV structural proteins. Analysis of the supernatant and precipitation of viral particles containing p54 showed that the protein is located in the lipid outer membrane of virions. p54 is also located by immunoelectron microscopy in the replication factories of infected cells (61). In order to track the behaviour of ASFV in the infected cells in real time, researchers produced an infectious recombinant ASFV to determine the trajectory and speed of intracellular virus movement and thereby visualise the ASFV factory formation dynamics (40). During the process of adaptation to tissue culture, the apparent molecular mass of p54 protein changes. p54 interacts with the microtubular motor complex via direct binding to the light chain 8 (LC8) of the dynein through a motif close to the C-terminus of the protein. The two proteins colocate at the microtubular organising centre during viral infection (3). The direct interaction of DYNLL1, the smallest dynein light chain, with the postsynaptic scaffolding protein gephyrin and the structural protein p54 has been shown by nuclear magnetic resonance (NMR) spectroscopy methods. The results showed that p54 and gephyrin are two targets of DYNLL1, and the sequences of these proteins contain GIQVD and KXTQT motifs with a glutamine which is important for binding (31, 32). p54 is essential for the recruitment of envelope precursors to assembly sites (62) and plays an important role in virus growth and inducing specific antibodies after inoculation of pigs with attenuated virus strains (61). Therefore, p54 expressed in a baculovirus and E. coli system has been exploited in serological diagnosis (29, 31). Antibodies to p54 protein inhibited the first step of the viral infection cycle related to viral attachment. Transient expression experiments of p54 in Vero cells demonstrated that p54 can activate the apoptosis of caspase-3 during the early phase of ASFV infection, and this was the first time an ASFV protein was reported to induce apoptosis (35, 39). Like p54, p30 is one of the early viral proteins. The protein is encoded by the CP204L gene, has a relative molecular weight of 30 kDa, and is one of the most antigenic structural proteins involved in ASFV entry (67). Expression of the protein is generally observed from about 2 to 4 h post-infection, and then continues throughout the infection cycle. Therefore, expression of p30 indicates that the virus has entered and uncoated, and early virus gene expression has started (47). The yeast two-hybrid system was used to screen a porcine macrophage cDNA library for cellular proteins that may interact with p30, and heterogeneous nuclear ribonucleoprotein K (hnRNP-K) was identified as the first cellular ligand of p30 (41). p54 and p30 are the antigenic proteins. Researchers demonstrated that a chimeric protein p54/30 retains antigenic determinants and the protein was expressed by a recombinant baculovirus in insect cells and Trichoplusiani larvae (8). The chimeric protein is strongly reactive with sera of pigs with unapparent ASFV infection (8). Oviedo et al. (58) found that recombinant p30 is more efficient than p54 for antibody detection by ELISA. Thus p30 should be used as the ELISA antigen, and p54 should be regarded as the appointed antigen for ASFV antibody detection by Western blot. Nevertheless, the combined use of p54 and p30 proteins for serological diagnosis of ASFV could improve the sensitivity of the method. Cubillos et al. (19) evaluated the reactivity of recombinant p30, p54, and p72 proteins simultaneously in a single reaction. The results showed that p30 is the best diagnostic antigen. Subsequently, Giménez et al. (33) developed a dual matrix indirect ELISA with recombinant p30 to flexibly detect ASFV antibodies in serum and oral fluid specimens. Antibody-mediated immune mechanisms have an important function in immunity to ASF. DNA vaccines encoding p54 and p30 fused together, namely plasmid DNA encoding two ASFV genes in a frame (pCMV-PQ), induced good antibody responses in mice (6). However, the neutralising antibody response to p54 and p30 is not sufficient for antibody-mediated protection in pigs (8, 54). Argilaguet et al. (7) found that DNA immunisation in pigs could be exponentially improved by adding the extracellular domain of the ASFV haemagglutinin (sHA) to p54 and p30, and pCMV-sHAPQ can induce strong humoral and cellular responses. p54 and p30 proteins serve as the important antigenic structural proteins in viral infection.

p72 protein

p72 protein with a relative molecular weight of 73.2 kDa is the major structural protein of ASFV, and it is the crucial antigenic protein encoded by the gene B646L (VP72). p72 with its highly antigenic and immunogenic character serves as the major component of viral icosahedrons. It is very important in forming the viral capsid in late stage expression of virus infection (54). Newly synthesised p72 is distributed evenly between a soluble cytoplasmic pool and a membrane-associated pool bound to the endoplasmic reticulum (ER), and assembles on the ER membrane to form the large capsid or matrix precursor (17). p72 protein was specifically immunoprecipitated by monoclonal antibody (mAb) 135D4 in vitro (11). The results showed that amino acid residues 400 and 404 are necessary for mAb 135D4 reactivity, and these suggested the conformational dependence of the epitope p72 in ASFV entry, and that its expression is an indicator of viral replication (47). A recombinant vaccine based on p72 and other viral proteins expressed in a baculovirus system was applied to immune pigs (54). p72 antibodies can prevent ASFV binding to macrophages, but the antibodies cannot play a decisive role in antibody-mediated immune protection (54). Chen et al. (16) constructed a recombinant Newcastle disease virus rNDV/p72 expressing ASFV p72 by reverse genetics, and they evaluated its humoral and cellular immunogenicity in a mouse model. The results showed that mice developed a high level of p72-specific IgG antibody. Sequence analysis of p72-coding genes from two ASFV strains from Uganda and the Dominican Republic (the latter strain Dominican Republic-2) demonstrated that p72 is highly conserved in strains isolated from different parts of the world. These proved that the antigenicity of p72 is stable and established a useful molecular basis for ASFV serological tests. Correspondingly, the VP72 gene of ASFV has been successfully expressed in E.coli using a T7 RNA polymerase system. The recombinant protein was purified by size-exclusion high-performance liquid chromatography and was used in serological tests. Sastre et al. (70) developed a duplex pen-side test for simultaneous detection and differentiation of antibodies specific to classical swine fever virus (CSFV) and to ASFV, and these tests were based on the major capsid protein p72 of ASFV and the structural protein E2 of CSFV. Some researchers used small interfering RNA (siRNA) targeting the VP72 and A151R genes to control ASFV replication in vitro(44). The results showed that siRNA targeting the genes can reduce both viral replication and the levels of messenger RNA transcripts. Discernible ASFV serotypes are lacking. Thus, the field strains are grouped genetically by sequencing the C-terminus of the p72 protein, and it provides additional valuable tools for future epidemiological assessment and elucidation of intra-genotypic relationships among the ASFV genotypes (9, 12, 48). Muangkram et al. (52) established a novel phylogenetic analysis and epidemiological comparison based on VP72 gene sequences. They found that 516 sequences of ASFV compiled from GenBank belonged to 44 different genotypes, and ASFV populations of the African continent could be divided into four clades by the analysis of spatial genetic variation. The immunodominant protein p72 revealed that 13 discrete genotypes were present in Eastern Africa (48). In order to target the single nucleotide polymorphisms (SNPs) in the C-terminal end of the VP72 gene region of the genome, a suspension microarray for the genotyping of ASFV has been developed (45), Gallardo et al. (31) confirmed the usefulness of a combined p72-p54-pB602L (CVR) gene characterisation approach for investigating the relatedness of ASF epizootics. The first isolate of ASFV from West Africa was successfully identified through PCR amplification and sequencing on the basis of a 280 bp fragment of the VP72 gene, in the course of which changes were found which had resulted in the loss of two out of the seven potential N-glycosylation sites which were conserved among all other isolates in this gene (57). To date, many assay methods have been developed based on the VP72 gene to detect ASFV, such as the linear after the exponential PCR (LATE-PCR), PCR, and real-time PCR (q-PCR) (37, 49, 64).

CD2v protein

CD2v protein, also named PEP402R, resembles the T-lymphocyte surface adhesion receptor CD2 and has a relative molecular weight of 105 kDa. It is a glycoprotein which is assembled from a signal peptide (SP), trans-membrane region (TM), and two immunoglobulin-like domains (IG). The cytosolic C-terminal domain of CD2v (CD2v-Ct) shares no obvious identity of amino acid sequence with that of the cellular CD2 cytoplasmic domain (25, 63). CD2v protein is expressed on T and NK cells. Moreover, confocal microscopy results suggested that the majority of the expressed CD2v protein is located within cells rather than on the cell surface. CD2v is located around viral factories during ASFV infection, and the regulatory trans-Golgi network (TGN) protein complex AP-1 is its target (34). The majority of CD2v appears to be located in perinuclear membrane compartments in the absence of an extracellular ligand (43), the protein is expressed late in infection, and the haemadsorption phenomenon is necessary for CD2v expression in ASFV-infected cells (63). CD2v can be cleaved into N-terminal glycosylated and C-terminal non-glycosylated forms, and this cleaving occurs in the endoplasmic reticulum or Golgi compartments; however, both of the forms coexist in the infected cell with the full length protein (34). CD2v protein is involved in cell-cell adhesion, virulence enhancement, and immune response modulation. Its possible role in the pathogenesis of ASFV infection, further role in tissue tropism, immune evasion, and enhancing virus replication in the host was demonstrated (65). CD2v protein can damage the function of lymphocytes, and the expression of this protein has some connection with ASFV spreading in domestic swine. The yeast two-hybrid system demonstrated the cytoplasmic tail of CD2v can interact with the cytoplasmic adaptor protein SH3P7, and protein SH3P7 is involved in diverse cellular functions such as vesicle transport and signal transduction (43). The cytoplasmic region of CD2v protein was proposed as a new genetic marker (69). This character could be used to analyse ASFV strains from different locations and track the virus spread. Serogroup classification of worldwide strains based on the extracellular portion of the protein can be established (13). The genetic locus encoding CD2v protein and C-type lectin proteins mediates HAI serological specificity, and ASFV CD2v and C type lectin signature sequencing provides a simple method to group ASFV by serotype. Thus it is readily exploitable for the study of ASFV strain diversity in nature and lays a good foundation for eventual vaccine design (50, 69). CD2v protein is encoded by the EP402R gene. Researchers found that deletion of the EP402R gene from the BA71V virus did not affect viral growth in Vero cell cultures. Frączyk et al. (24) first reported the genetic variability within the gene related to evasion of the host immune system, and they found minor but remarkable genetic diversity in the EP402R gene and demonstrated the slow molecular evolution of circulating ASFV isolates. Comparison of the EP402R gene of ASFV strains collected from 1978 to 2014 showed that Sardinian viruses can be divided into two subgroups. One group includes the historical isolates from 1978 to 1990, and the second group contains the viruses recovered from 1990 to 2014 (69). It was found that the EP402R and EP153R genes are disrupted in the genome of a natural non-haemadsorbing (non-HAD) isolate with low virulence, the isolate ASFV/NH/P68 (46). However, two recombinant HAD viruses replicated to titre approximately 1,000-fold higher than the non-HAD isolate when the intact EP153R gene was restored. Although the restoration did not increase virus virulence, the symptom of viraemia was observed in a number of pigs, and these results demonstrated a novel role of CD2v protein in virus replication in ticks (65).

Other structural proteins

pp220, pp62, p54, p30, p72, and CD2v proteins have been identified as important structural proteins in viral attachment, entry, immune response modulation in the host, and as major components of virions. Besides these, some other structural proteins, such as p10, p12, p14.5, and p17, are encoded by the ASFV genome. They also have important roles in viral infection. p10 protein, with a relative molecular weight of 8.4 kDa, is encoded by the K78R gene. The protein is an extremely hydrophilic polypeptide with a relatively high content of basic residues (23%) and is accumulated in the cell nucleus during viral infection (55). p10 is involved in ASFV adsorption and has DNA binding capacity, either single- or double-stranded (55). The nuclear import ability of p10 was assessed by yeast-based nuclear import assay and the subcellular localisation of p10 in mammalian cells was examined by fluorescence microscopy. The results showed that the protein is actively imported into the nucleus, and 71 to 73 amino acids of p10 are important for the nuclear import (60). p12 protein with a cysteine-rich domain in the C-terminal region is encoded by the O61R gene, and is synthesised in the late phase of viral infection (27). Its location in the layer of virions was demonstrated by immunoelectron microscopy. p12 is involved in virus attachment to the host cells, and the membrane proteins on the surface of permissive cells act as receptors for ASFV (14). p14.5 protein, also called pE120R, is encoded by the E120R gene. It is a DNA binding protein with a relative molecular weight of 13.6 kDa. p14.5 is synthesised during the late phase of viral infection, and is the necessary protein involved in transferring virions from viral factories to the plasma membrane (5). The posttranslational modifications of pE120R have been described using two-dimensional gel electrophoresis (2DE) and mass spectrometry (MS), and it was found that the protein was acetylated at the N-terminal alanine (Ala) residue during viral infection (2). p17 is a major structural protein of ASFV and is a trans-membrane protein localised at the viral internal envelope. The protein is essential for the progression of viral membrane precursors toward icosahedral intermediates and virus viability (72).

Conclusions

There are many proteins encoded by the ASFV genome. These proteins have roles in various stages of the viral infection cycle (Table 1). More than 50 proteins are packaged into virus particles and are the major constituent of virus particles playing a role in the early stages of virus infection. pp220 and pp62 proteins form the major components of the core shell in virions. pp220 and pp62 can be cleaved to yield the mature virion proteins p150, p37, p14, p34, p35, and p15 by the virus-encoded SUMO-like protease S273R. These proteins have an important role in the assembly process of the viral capsid. p54 locates on the lipid outer membrane of viral particles, and is involved in ASFV entry and serves as the trans-membrane structural protein. p54 is critical for the recruitment and transformation of the ER membranes into the precursors of the viral envelope. This protein, together with p30 and other proteins, is regarded as a viable antigen protein in developing serological diagnosis. p72 with its highly antigenic and immunogenic character serves as the major component of viral icosahedrons. The protein locates on the surface of the viral capsid and is expressed late in viral infection. Gene VP72 is used to type the ASFV gene by the sequence of the C-terminus in the VP72 gene, and it is central to a new method for molecular epidemiological research. CD2v is a glycoprotein and can cause the adsorption of red blood cells around ASFV infected cells and extracellular viral particles. The molecular mechanisms of the function of CD2v protein are not clear, but researchers found that the protein locates around viral factories during ASFV infection. Some other structural proteins, such as p10, p12, p14.5, and p17, are involved in ASFV attachment, entry, and replication.
Table 1

The structural proteins involved in ASFV infection

Protein's nameGene namePredicted protein size (kDa)Protein's function
p11.5A137R21.1Involved in virus attachment
p10A78R8.4Involved in virus attachment
p72B646L73.2Major capsid protein, involved in virus entry
pp220CP2475L281.5Polyprotein precursor of p150, p37, p14, and p34; required for packaging of nucleoprotein core
p32(p30)CP204L23.6Phosphorylated and antigenic protein, involved in virus entry
pp62 (p60)CP530R60.5Polyprotein precursor of p35 and p15
p12O61R6.7Attachment protein
p17D117L13.1Required for progression of precursor membranes to icosahedral intermediates
p54 (j13L)E183L19.9Binds to LC8 chain of dynein, involved in virus entry; required for recruitment of envelope precursors to the factory
p14.5E120R13.6DNA-binding protein, required for movement of virions to plasma membrane
CD2v (PEP402R)EP402R45.3Similar to host CD2 protein, required for binding red blood cells to infected cells and extracellular virus particles; glycoprotein inserted into external virus envelope
The structural proteins involved in ASFV infection The major target cells of ASFV are swine monocyte-macrophages, but the virus is found in many other cells in the late phase of viral infection. The viral entry mechanism determines viral tropism and pathogenesis, and the pathway of entry in target cells is a dynamin-dependent and clathrin-mediated macropinocytosis process. Present knowledge attests that some viral proteins are involved in ASFV attachment and entry, but the receptors of these proteins are unclear. The viral core transfers to the perinuclear region following ASFV entry into cells, and it starts the early mRNA transcription and translation using enzymes and cytokines. These enzymes and cytokines are packed into the virion interior to provide DNA polymerase of viral replication. ASFV starts its replication in the cytoplasm 6 h after viral infection. The structural proteins and the enzymes packed into mature virions are encoded at this stage. Transferring the expression from the early gene to the late one is an indicator of the start of ASFV replication. The subsequent procedures include virion assembly in cytoplasm around the nucleus, and the virus nucleoprotein core is packaged to form viral capsid with icosahedrons by the membrane from the double membrane of ER. The packed ASFV is transferred to the plasma membrane by microtubules, and then viral particles bud through the plasma membrane. At last, mature viral particles exit from the host cells. Additional experiments are needed to illustrate the molecular mechanism of the structural proteins involved in ASFV infection of target cells, although extensive studies have been carried out. Better understanding of the precise mechanism will facilitate the prevention and control of the spread of ASF in the world.
  75 in total

1.  African swine fever virus protein p17 is essential for the progression of viral membrane precursors toward icosahedral intermediates.

Authors:  Cristina Suárez; Javier Gutiérrez-Berzal; Germán Andrés; María L Salas; Javier M Rodríguez
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  African swine fever virus infects macrophages, the natural host cells, via clathrin- and cholesterol-dependent endocytosis.

Authors:  Inmaculada Galindo; Miguel Angel Cuesta-Geijo; Karolina Hlavova; Raquel Muñoz-Moreno; Lucía Barrado-Gil; Javier Dominguez; Covadonga Alonso
Journal:  Virus Res       Date:  2015-02-03       Impact factor: 3.303

3.  Enhancing DNA immunization by targeting ASFV antigens to SLA-II bearing cells.

Authors:  J M Argilaguet; E Pérez-Martín; C Gallardo; F J Salguero; B Borrego; A Lacasta; F Accensi; I Díaz; M Nofrarías; J Pujols; E Blanco; M Pérez-Filgueira; J M Escribano; F Rodríguez
Journal:  Vaccine       Date:  2011-06-14       Impact factor: 3.641

Review 4.  African swine fever virus replication and genomics.

Authors:  Linda K Dixon; David A G Chapman; Christopher L Netherton; Chris Upton
Journal:  Virus Res       Date:  2012-11-08       Impact factor: 3.303

5.  Recombinant Newcastle disease virus expressing African swine fever virus protein 72 is safe and immunogenic in mice.

Authors:  Xinxin Chen; Jifei Yang; Yanhong Ji; Edward Okoth; Bin Liu; Xiaoyang Li; Hong Yin; Qiyun Zhu
Journal:  Virol Sin       Date:  2016-03-11       Impact factor: 4.327

6.  African swine fever virus CD2v and C-type lectin gene loci mediate serological specificity.

Authors:  A Malogolovkin; G Burmakina; E R Tulman; G Delhon; D G Diel; N Salnikov; G F Kutish; D Kolbasov; D L Rock
Journal:  J Gen Virol       Date:  2014-12-18       Impact factor: 3.891

7.  Design and verification of a highly reliable Linear-After-The-Exponential PCR (LATE-PCR) assay for the detection of African swine fever virus.

Authors:  B Ronish; M Hakhverdyan; K Ståhl; C Gallardo; J Fernandez-Pinero; S Belák; N Leblanc; L Wangh
Journal:  J Virol Methods       Date:  2010-12-15       Impact factor: 2.014

8.  High level expression of the major antigenic African swine fever virus proteins p54 and p30 in baculovirus and their potential use as diagnostic reagents.

Authors:  J M Oviedo; F Rodríguez; P Gómez-Puertas; A Brun; N Gómez; C Alonso; J M Escribano
Journal:  J Virol Methods       Date:  1997-02       Impact factor: 2.014

9.  The non-haemadsorbing African swine fever virus isolate ASFV/NH/P68 provides a model for defining the protective anti-virus immune response.

Authors:  Alexandre Leitão; Clara Cartaxeiro; Ricardo Coelho; Benedita Cruz; R M E Parkhouse; Fernando C Portugal; José D Vigário; Carlos L V Martins
Journal:  J Gen Virol       Date:  2001-03       Impact factor: 3.891

10.  African Swine Fever Epidemic, Poland, 2014-2015.

Authors:  Krzysztof Śmietanka; Grzegorz Woźniakowski; Edyta Kozak; Krzysztof Niemczuk; Magdalena Frączyk; Łukasz Bocian; Andrzej Kowalczyk; Zygmunt Pejsak
Journal:  Emerg Infect Dis       Date:  2016-07       Impact factor: 6.883

View more
  21 in total

1.  A novel function of African Swine Fever Virus pE66L in inhibition of host translation by the PKR/eIF2α pathway.

Authors:  Zhou Shen; Chen Chen; Yilin Yang; Zhenhua Xie; Qingying Ao; Lu Lv; Shoufeng Zhang; Huanchun Chen; Rongliang Hu; Hongjun Chen; Guiqing Peng
Journal:  J Virol       Date:  2020-12-16       Impact factor: 5.103

2.  An extensive evaluation of codon usage pattern and bias of structural proteins p30, p54 and, p72 of the African swine fever virus (ASFV).

Authors:  Uma Bharathi Indrabalan; Kuralayanapalya Puttahonnappa Suresh; Chandan Shivamallu; Sharanagouda S Patil
Journal:  Virusdisease       Date:  2021-07-22

3.  Development and application of a colloidal-gold dual immunochromatography strip for detecting African swine fever virus antibodies.

Authors:  Ying Wan; Zhengwang Shi; Gaochaung Peng; Lijuan Wang; Juncong Luo; Yi Ru; Gaijing Zhou; Yuan Ma; Rui Song; Bo Yang; Liyan Cao; Hong Tian; Haixue Zheng
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-23       Impact factor: 4.813

4.  Transcriptome profile of spleen tissues from locally-adapted Kenyan pigs (Sus scrofa) experimentally infected with three varying doses of a highly virulent African swine fever virus genotype IX isolate: Ken12/busia.1 (ken-1033).

Authors:  Eunice Magoma Machuka; John Juma; Anne Wangari Thairu Muigai; Joshua Oluoch Amimo; Roger Pelle; Edward Okoth Abworo
Journal:  BMC Genomics       Date:  2022-07-19       Impact factor: 4.547

5.  SPR-Based Detection of ASF Virus in Cells.

Authors:  Alessandro Capo; Alessia Calabrese; Maciej Frant; Marek Walczak; Anna Szczotka-Bochniarz; Georgios Manessis; Ioannis Bossis; Maria Staiano; Sabato D'Auria; Antonio Varriale
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

6.  FoxJ1 inhibits African swine fever virus replication and viral S273R protein decreases the expression of FoxJ1 to impair its antiviral effect.

Authors:  Caina Ma; Shasha Li; Fan Yang; Weijun Cao; Huisheng Liu; Tao Feng; Keshan Zhang; Zixiang Zhu; Xiangtao Liu; Yonghao Hu; Haixue Zheng
Journal:  Virol Sin       Date:  2022-05-02       Impact factor: 6.947

Review 7.  Transcriptome view of a killer: African swine fever virus.

Authors:  Gwenny Cackett; Michal Sýkora; Finn Werner
Journal:  Biochem Soc Trans       Date:  2020-08-28       Impact factor: 5.407

8.  Characteristics of Selected Active Substances used in Disinfectants and their Virucidal Activity Against ASFV.

Authors:  Małgorzata Juszkiewicz; Marek Walczak; Grzegorz Woźniakowski
Journal:  J Vet Res       Date:  2019-03-22       Impact factor: 1.744

9.  Assessment of Risk Factors of African Swine Fever in India: Perspectives on Future Outbreaks and Control Strategies.

Authors:  Mousumi Bora; Durlav Prasad Bora; Mohan Manu; Nagendra Nath Barman; Lakshya Jyoti Dutta; Pesingi Pavan Kumar; Suvaneeth Poovathikkal; Kuralayanapalya Puttahonnappa Suresh; Ramadevi Nimmanapalli
Journal:  Pathogens       Date:  2020-12-12

10.  A Productive Expression Platform Derived from Host-Restricted Eilat Virus: Its Extensive Validation and Novel Strategy.

Authors:  Lu Tan; Yiwen Zhang; Xingxing Wang; Dal Young Kim
Journal:  Viruses       Date:  2021-04-11       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.